Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
| Autor: | Lin Zhao, Suzanne Oparil, Attila Juhasz, George L. Bakris, Michie Hisada, Stuart Kupfer, Eric E. Lloyd |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Urology 030204 cardiovascular system & hematology Hypertension Therapy Nephropathy 03 medical and health sciences 0302 clinical medicine Hydrochlorothiazide Internal Medicine Medicine Humans 030212 general & internal medicine Azilsartan Medoxomil Renal Insufficiency Chronic Adverse effect Aged Oxadiazoles Olmesartan Medoxomil business.industry Chlorthalidone Middle Aged medicine.disease Treatment Outcome Tolerability Hypertension Benzimidazoles Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Olmesartan Kidney disease medicine.drug |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1751-7176 |
| Popis: | An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL-M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up-titrated (AZL-M/CLD to 40/25 mg; OLM/HCTZ to 40/25 mg [US] or 20/25 mg [Europe]) with other agents added during weeks 4-52. Primary endpoint was proportion of participants with ≥ 1 adverse event (AE) through week 52. Baseline demographics were similar. AEs did not differ between groups (88.3%, AZL-M/CLD vs 76.3%, OLM/HCTZ; P = .058). AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = .037) but not during long-term follow-up (P = .588). A greater proportion of participants up-titrated to the highest dose with OLM/HCTZ (48.7%) vs AZL-M/CLD (29.9%) (P = .021) and were taking additional antihypertensive medications (26.3% vs 16.9%). Both AZL-M/CLD and OLM/HCTZ showed similar efficacy and tolerability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|